ATE381542T1 - Nr1h4-kern-rezeptor-bindende verbindungen - Google Patents
Nr1h4-kern-rezeptor-bindende verbindungenInfo
- Publication number
- ATE381542T1 ATE381542T1 AT01119473T AT01119473T ATE381542T1 AT E381542 T1 ATE381542 T1 AT E381542T1 AT 01119473 T AT01119473 T AT 01119473T AT 01119473 T AT01119473 T AT 01119473T AT E381542 T1 ATE381542 T1 AT E381542T1
- Authority
- AT
- Austria
- Prior art keywords
- nr1h4
- receptor binding
- binding compounds
- compounds
- core receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/11—Compounds covalently bound to a solid support
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01119473A EP1285914B1 (de) | 2001-08-13 | 2001-08-13 | Nr1h4-kern-rezeptor-bindende verbindungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE381542T1 true ATE381542T1 (de) | 2008-01-15 |
Family
ID=8178316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01119473T ATE381542T1 (de) | 2001-08-13 | 2001-08-13 | Nr1h4-kern-rezeptor-bindende verbindungen |
Country Status (5)
Country | Link |
---|---|
US (3) | US7034046B2 (de) |
EP (3) | EP1285914B1 (de) |
AT (1) | ATE381542T1 (de) |
DE (1) | DE60131967D1 (de) |
WO (2) | WO2003015771A1 (de) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4021327B2 (ja) | 2001-03-12 | 2007-12-12 | インターセプト ファーマスーティカル インコーポレイテッド | Fxrに対する作用薬としてのステロイド |
US6987121B2 (en) * | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
WO2003099793A1 (en) * | 2002-05-24 | 2003-12-04 | Takeda Pharmaceutical Company Limited | 1,2-azole derivatives with hypoglycemic and hypolipidemic activity |
WO2004048349A1 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
BRPI0414812A (pt) * | 2003-09-26 | 2006-11-14 | Forbes Medi Tech Inc | método de inibir a expressão de genes resistentes a múltiplos medicamentos e de inibir a produção de proteìnas resultantes da expressão de tais gene, melhorando assim a efetividade dos agentes quimioterápicos para tratar cánceres |
WO2005042692A2 (en) * | 2003-10-31 | 2005-05-12 | Forbes Medi-Tech Inc. | A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors |
AU2006249350B2 (en) | 2003-11-19 | 2012-02-16 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
EP2428516A1 (de) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Neue Phosphor enthaltende Thyromimetika |
PT1700856E (pt) * | 2003-12-26 | 2016-02-19 | Kyowa Hakko Kirin Co Ltd | Derivado de tiazole |
DK2712617T3 (en) | 2004-03-12 | 2017-02-13 | Intercept Pharmaceuticals Inc | Treatment of fibrosis with Fxr ligands. |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
US20060019907A1 (en) * | 2004-07-12 | 2006-01-26 | Research Development Foundation | Guggulsterone: an inhibitor of nuclear factor - kappaB and IkappaBalpha kinase activation and uses thereof |
BRPI0513677B8 (pt) | 2004-07-30 | 2021-05-25 | Exelixis Inc | derivados de pirrol como agentes farmacêuticos |
WO2006029719A2 (en) * | 2004-09-14 | 2006-03-23 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with nuclear receptor subfamily 1, group h, member 4 (nr1h4) |
US20060252670A1 (en) * | 2004-10-14 | 2006-11-09 | Intercept Pharmaceuticals Inc. | Method of reducing drug-induced adverse side effects in a patient |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
US7618956B2 (en) * | 2005-05-31 | 2009-11-17 | The Gillette Company | Reduction of hair growth |
WO2007052843A1 (ja) * | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
WO2007076260A2 (en) | 2005-12-19 | 2007-07-05 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
BRPI0707427A2 (pt) | 2006-02-03 | 2011-05-03 | Lilly Co Eli | composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar dislipidemia, aterosclerose, e diabetes e complicações da mesma, para elevar os nìveis plásmicos de hdl, e para diminuir triglicerìdeos plásmicos, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo |
TW200812982A (en) | 2006-05-24 | 2008-03-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
WO2007140183A1 (en) | 2006-05-24 | 2007-12-06 | Eli Lilly And Company | Fxr agonists |
EP1886685A1 (de) * | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors |
EP1894924A1 (de) * | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterozyklische FXR Bindungsverbindungen |
EP1894928A1 (de) * | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Fxr bindende heterocyclische verbindungen |
CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
MX2009007728A (es) | 2007-01-19 | 2009-12-15 | Intercept Pharmaceuticals Inc | Acidos biliares 23-sustituidos como moduladores de tgr5 y metodos de uso de los mismos. |
MX2009013946A (es) * | 2007-07-02 | 2010-03-10 | Glaxosmithkline Llc | Agonistas del receptor de farnesoide x. |
TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
CN101883769B (zh) | 2007-12-04 | 2012-08-08 | 弗·哈夫曼-拉罗切有限公司 | 异噁唑-吡嗪衍生物 |
US7902201B2 (en) | 2007-12-04 | 2011-03-08 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
EP2128158A1 (de) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclische Cyclopropyl-substituierte FXR-bindende Verbindungen |
WO2010014836A2 (en) | 2008-07-30 | 2010-02-04 | Intercept Pharmaceuticals, Inc. | Tgr5 modulators and methods of use thereof |
CA2740366A1 (en) * | 2008-10-21 | 2010-04-29 | Metabolex, Inc. | Aryl gpr120 receptor agonists and uses thereof |
KR101789960B1 (ko) * | 2008-11-19 | 2017-10-25 | 인터셉트 파마슈티컬즈, 인크. | Tgr5 조절제 및 그의 사용 방법 |
US20110257139A1 (en) | 2008-12-19 | 2011-10-20 | Royal College Of Surgeons In Ireland | Treatment of diarrhoea |
TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
CA2760166C (en) | 2009-05-05 | 2017-07-18 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
MX2011011490A (es) | 2009-05-05 | 2011-11-18 | Hoffmann La Roche | Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos. |
EP2427458B1 (de) | 2009-05-05 | 2014-05-07 | F.Hoffmann-La Roche Ag | Isoxazol-Pyridazin-Derivate |
KR101384829B1 (ko) | 2009-05-05 | 2014-04-15 | 에프. 호프만-라 로슈 아게 | 이속사졸-피라졸 유도체 |
WO2010127978A1 (en) | 2009-05-07 | 2010-11-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as gaba modulators |
EP2289883A1 (de) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Neue Aktivitätsmodulationsverbindungen für FXR- (NR1H4) |
EP2545964A1 (de) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Neuartige FXR- (NR1H4)-Binde- und -Aktivitätsmodulationsverbindungen |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
CN104781272A (zh) | 2012-06-19 | 2015-07-15 | 英特塞普特医药品公司 | 奥贝胆酸的制备、用途和固体形式 |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
AU2014320463B2 (en) | 2013-09-11 | 2018-08-02 | Centre National De La Recherche Scientifique (Cnrs) | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection |
EP3006939A1 (de) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidinreiches Glycoprotein als Marker zur hepatischen Farnesoid-X-Aktivierung |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
EP3034501A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxyhaltige FXR (NR1H4) modulierende Verbindungen |
EP3034499A1 (de) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Neuartige FXR (NR1H4) modulierende Verbindungen |
MA40814A1 (fr) | 2015-02-06 | 2019-08-30 | Intercept Pharmaceuticals Inc | Compositions pharmaceutiques pour thérapie combinée |
TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
CN107427527B (zh) | 2015-03-31 | 2021-01-26 | 英安塔制药有限公司 | 作为fxr/tgr5激动剂的胆汁酸衍生物及其使用方法 |
KR20170132879A (ko) | 2015-04-07 | 2017-12-04 | 인터셉트 파마슈티컬즈, 인크. | 조합 요법을 위한 약제학적 조성물 |
US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
US10080743B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
US10138228B2 (en) | 2016-05-18 | 2018-11-27 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use therof |
WO2017201155A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
WO2017201150A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
BR112019006651A2 (pt) | 2016-10-04 | 2019-07-02 | Enanta Pharm Inc | análogos de isoxazol como agonistas de fxr e métodos de uso do mesmo |
US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
MX2019005730A (es) | 2016-11-21 | 2019-10-21 | Viking Therapeutics Inc | Metodo para tratar enfermedad de almacenamiento de glucogeno. |
ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
NZ758117A (en) | 2017-04-12 | 2022-01-28 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
EA201992703A1 (ru) | 2017-06-05 | 2020-04-15 | Вайкинг Терапьютикс, Инк. | Композиции для лечения фиброза |
EP3704107B1 (de) | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Multizyklische verbindungen als farnesoid-x-rezeptormodulatoren |
ES2944657T3 (es) | 2017-11-01 | 2023-06-23 | Bristol Myers Squibb Co | Compuestos de alqueno como moduladores del receptor farnesoide X |
BR112020008121A2 (pt) | 2017-11-01 | 2020-11-03 | Bristol-Myers Squibb Company | compostos espirocíclico de alqueno como moduladores de receptor farnesoide x |
US10689391B2 (en) | 2017-12-12 | 2020-06-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
AU2019238090A1 (en) | 2018-03-22 | 2020-10-08 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
IT201800007265A1 (it) * | 2018-07-17 | 2020-01-17 | Isossazoli come agonisti del recettore fxr | |
DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
JP2022536060A (ja) | 2019-05-30 | 2022-08-12 | インターセプト ファーマシューティカルズ, インコーポレイテッド | 胆汁鬱滞性肝疾患の処置で使用するためのfxrアゴニストおよびフィブラートを含む医薬組成物 |
MX2022000742A (es) | 2019-07-18 | 2022-02-14 | Enyo Pharma | Metodo para disminuir los efectos adversos del interferon. |
CN112824394A (zh) * | 2019-11-21 | 2021-05-21 | 中国科学院上海药物研究所 | PPARs-FXR多靶点小分子激动剂及其制备方法和用途 |
EP4090327A1 (de) | 2020-01-15 | 2022-11-23 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Verwendung des fxr-agonisten zur behandlung einer infektion durch das hepatitis-d-virus |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN117202905A (zh) | 2021-01-14 | 2023-12-08 | 埃尼奥制药公司 | Fxr激动剂和ifn用于治疗hbv感染的协同效果 |
JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2863874A (en) * | 1955-05-26 | 1958-12-09 | Goodrich Co B F | Process of preparing 2-aminothiazoles |
AU545463B2 (en) * | 1982-06-25 | 1985-07-18 | Kowa Co. Ltd. | Benzoyl piperacine esters |
JPS59139357A (ja) * | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
DE3621372A1 (de) * | 1986-06-26 | 1988-01-07 | Thomae Gmbh Dr K | Heterocyclisch substituierte 3,5-dihydroxy-hept-6-en-carbonsaeuren, ihre derivate, verfahren zur herstellung dieser verbindungen und die sie enthaltende arzneimittel |
DE4237768A1 (en) * | 1991-11-12 | 1993-05-13 | Ciba Geigy Ag | New polyarylene ether derivs. with reduced viscosity - used to prepare moulded bodies, foils, fibres and membranes, as matrix resins, adhesives or coating agents or as polymer additives |
DE4219247A1 (de) * | 1992-06-12 | 1993-12-16 | Bayer Ag | Verwendung von 3-arylsubstituierten 5-Alkyl-isoxazol-4-carbonsäurederivaten zur Bekämpfung von Endoparasiten, neue 3-arylsubstituierte 5-Alkyl-isoxazol-4-carbonsäurederivate und Verfahren zu ihrer Herstellung |
FR2692893B1 (fr) * | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
US6005103A (en) * | 1993-11-19 | 1999-12-21 | Warner-Lambert Company | Pyrone derivatives as protease inhibitors and antiviral agents |
FR2714059B1 (fr) * | 1993-12-21 | 1996-03-08 | Sanofi Elf | Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
CA2195847A1 (en) * | 1994-07-27 | 1996-02-08 | John J. Talley | Substituted thiazoles for the treatment of inflammation |
EP0790057B1 (de) * | 1994-11-29 | 2002-06-05 | Hisamitsu Pharmaceutical Co., Inc. | Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten |
RU2200158C2 (ru) * | 1995-02-13 | 2003-03-10 | Джи.Ди.Сирл энд Ко. | Замещенные изоксазолы, фармацевтические композиции на их основе и способ подавления воспалений |
US5786355A (en) * | 1995-04-13 | 1998-07-28 | Taiho Pharmaceutical Co., Ltd. | 4,6-diarylpyrimidine derivatives and salts thereof |
JP4136024B2 (ja) | 1995-12-29 | 2008-08-20 | 富山化学工業株式会社 | 2−アミノチアゾ−ル誘導体またはその塩 |
US5883105A (en) | 1996-04-03 | 1999-03-16 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
JPH11263775A (ja) * | 1997-09-08 | 1999-09-28 | Sankyo Co Ltd | ヒドロキシアニリン誘導体 |
US6262098B1 (en) * | 1998-08-07 | 2001-07-17 | Chiron Corporation | Estrogen receptor modulators |
EP1140079B1 (de) * | 1998-12-23 | 2009-06-03 | Glaxo Group Limited | Bestimmungsmethode fur liganden der nuklearen rezeptoren |
US6201020B1 (en) * | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
SK15522001A3 (sk) * | 1999-04-28 | 2002-06-04 | Aventis Pharma Deutschland Gmbh | Deriváty kyselín s tromi arylovými zvyškami ako ligandy receptorov PPAR a farmaceutické kompozície, ktoré ich obsahujú |
DE19943636A1 (de) * | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
GB2361236B (en) * | 2000-03-29 | 2002-04-24 | Cyclacel Ltd | Pyrimidines useful against proliferative disorders |
GB0030710D0 (en) * | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
-
2001
- 2001-08-13 AT AT01119473T patent/ATE381542T1/de not_active IP Right Cessation
- 2001-08-13 DE DE60131967T patent/DE60131967D1/de not_active Expired - Lifetime
- 2001-08-13 EP EP01119473A patent/EP1285914B1/de not_active Expired - Lifetime
-
2002
- 2002-07-01 US US10/185,721 patent/US7034046B2/en not_active Expired - Lifetime
- 2002-07-01 US US10/185,731 patent/US6974830B2/en not_active Expired - Lifetime
- 2002-08-13 EP EP02750473A patent/EP1423111A4/de not_active Withdrawn
- 2002-08-13 EP EP02750472A patent/EP1423370A4/de not_active Withdrawn
- 2002-08-13 WO PCT/US2002/025437 patent/WO2003015771A1/en not_active Application Discontinuation
- 2002-08-13 WO PCT/US2002/025436 patent/WO2003016288A1/en not_active Application Discontinuation
- 2002-08-13 US US10/217,141 patent/US7098336B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1423370A4 (de) | 2007-04-18 |
EP1423111A1 (de) | 2004-06-02 |
US6974830B2 (en) | 2005-12-13 |
US7098336B2 (en) | 2006-08-29 |
WO2003015771A1 (en) | 2003-02-27 |
US20030187042A1 (en) | 2003-10-02 |
US7034046B2 (en) | 2006-04-25 |
EP1423370A1 (de) | 2004-06-02 |
US20030130296A1 (en) | 2003-07-10 |
EP1423111A4 (de) | 2007-04-18 |
WO2003016288A1 (en) | 2003-02-27 |
US20030149087A1 (en) | 2003-08-07 |
DE60131967D1 (de) | 2008-01-31 |
EP1285914A1 (de) | 2003-02-26 |
EP1285914B1 (de) | 2007-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE381542T1 (de) | Nr1h4-kern-rezeptor-bindende verbindungen | |
ATE396186T1 (de) | Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5 | |
EA200301216A1 (ru) | Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания | |
DE60231341D1 (de) | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
MEP45308A (en) | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | |
CY1106969T1 (el) | Αναστολεις dpp-iv | |
BG108650A (en) | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | |
SE0303180D0 (sv) | Novel compounds | |
SE0302232D0 (sv) | Novel Compounds | |
ATE515505T1 (de) | Heterocyclische fxr-bindende verbindungen | |
EA200601266A1 (ru) | Соединения триазола и их применение в качестве антагонистов метаботропного рецептора глутамата | |
BRPI0000596B8 (pt) | composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto | |
NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
DE60237528D1 (de) | Neue aminoazetidin-, aminopyrrolidin- und aminopiperidinderivative | |
EP1398029A8 (de) | 3-substituierte Pyrazol-Derivate,die an den NR3B1 Rezeptor binden | |
SE0301368D0 (sv) | Chemical compounds | |
NO20050270L (no) | Nye forbindelser, deres anvendelse og fremstilling | |
EA200400454A1 (ru) | Мускариновые агонисты | |
EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
ATE370147T1 (de) | Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors | |
ATE386738T1 (de) | Flavaxat-derivate als muscarin-rezeptor antagonisten | |
EA200501594A1 (ru) | Замещенные производные азабициклогексана в качестве антагонистов мускаринового рецептора | |
ATE398614T1 (de) | Triazolverbindungen und ihre therapeutische verwendung | |
DK1347965T3 (da) | Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |